News & Updates
Filter by Specialty:
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
Transplant-ineligible myeloma: Daratumumab added to VCD deepens haematological response, improves PFS
Addition of daratumumab to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen provides deeper haematological responses and improves progression-free survival (PFS) in patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplantation (ASCT), according to the results of the AMaRC 03-16 phase II study.
Transplant-ineligible myeloma: Daratumumab added to VCD deepens haematological response, improves PFS
20 Aug 2024
Adding anlotinib to gefitinib improves PFS in treatment-naïve Chinese patients with EGFRmut NSCLC
Adding anlotinib to gefitinib significantly improves progression-free survival (PFS) in treatment-naïve Chinese patients with EGFR-mutated (EGFRmut) advanced non-small-cell lung cancer (NSCLC), according to the results of the FL-ALTER phase III study.
Adding anlotinib to gefitinib improves PFS in treatment-naïve Chinese patients with EGFRmut NSCLC
20 Aug 2024
Ongoing treatment required in severe patchy hair loss
For patients with severe alopecia areata who achieved meaningful hair regrowth with 1-year course of baricitinib, subsequent discontinuation appears to reverse treatment gains, highlighting the need for ongoing therapy.
